ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Anixa Biosciences Inc
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026
$2.61−0.06 (-2.25%)
Close on Oct 19, 2026
- Market cap
- $89.22M
- P/E (TTM)
- –
- Dividend yield
- –
Anixa Biosciences Inc revenue by segment
By business segment
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Other [Member] | -$54.00K | -$60.00K | – | – | – | – | – | – | – | – | -10.0% |
| CAR-T Therapeutics [Member] | -$4.45M | -$5.73M | – | – | – | – | – | – | – | – | -22.3% |
| Cancer Vaccines [Member] | -$7.39M | -$8.04M | – | – | – | – | – | – | – | – | -8.0% |
By product or service
By region
From the segment and revenue-disaggregation notes of Anixa Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.